156 related items for PubMed ID: 35649383
1. Do All Patients with Congenital Adrenal Hyperplasia Need to Be on Hydrocortisone Three Times a Day in Order to Have Normal Growth?
Logan LA, Nebesio TD, Eckert GJ, Eugster EA.
Horm Res Paediatr; 2022; 95(5):461-464. PubMed ID: 35649383
[Abstract] [Full Text] [Related]
2. Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia.
Ng SM, Stepien KM, Krishan A.
Cochrane Database Syst Rev; 2020 Mar 19; 3(3):CD012517. PubMed ID: 32190901
[Abstract] [Full Text] [Related]
3. Long-term prednisone versus hydrocortisone treatment in children with classic Congenital Adrenal Hyperplasia (CAH) and a brief review of the literature.
Ahmed SEAM, Soliman AT, Ramadan MA, Elawwa A, Abugabal AMS, Emam MHA, De Sanctis V.
Acta Biomed; 2019 Sep 06; 90(3):360-369. PubMed ID: 31580328
[Abstract] [Full Text] [Related]
4. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Völkl TM, Simm D, Beier C, Dörr HG.
Pediatrics; 2006 Jan 06; 117(1):e98-105. PubMed ID: 16396852
[Abstract] [Full Text] [Related]
5. Twice Daily Compared to Three Times Daily Hydrocortisone in Prepubertal Children with Congenital Adrenal Hyperplasia.
Apsan J, Thomas C, Elnaas H, Lin-Su K, Lekarev O.
Horm Res Paediatr; 2022 Jan 06; 95(1):62-67. PubMed ID: 35220302
[Abstract] [Full Text] [Related]
6. Impact of hydrocortisone on adult height in congenital adrenal hyperplasia-the Minnesota cohort.
Sarafoglou K, Addo OY, Turcotte L, Otten N, Wickremasinghe A, Pittock S, Kyllo J, Lteif AN, Himes JH, Miller BS.
J Pediatr; 2014 May 06; 164(5):1141-1146.e1. PubMed ID: 24560184
[Abstract] [Full Text] [Related]
7. Leukocyte Telomere Length in Children With Congenital Adrenal Hyperplasia.
Raftopoulou C, Abawi O, Sommer G, Binou M, Paltoglou G, Flück CE, van den Akker ELT, Charmandari E.
J Clin Endocrinol Metab; 2023 Jan 17; 108(2):443-452. PubMed ID: 36181470
[Abstract] [Full Text] [Related]
8. Impact of availability of oral hydrocortisone on growth of children with CAH.
Khadilkar VV, Khadilkar AV, Maskati GB.
Indian J Pediatr; 2005 Apr 17; 72(4):301-3. PubMed ID: 15876756
[Abstract] [Full Text] [Related]
9. Growth of patients with congenital adrenal hyperplasia due to 21-hydroxylase in infancy, glucocorticoid requirement and the role of mineralocorticoid therapy.
Sellick J, Aldridge S, Thomas M, Cheetham T.
J Pediatr Endocrinol Metab; 2018 Sep 25; 31(9):1019-1022. PubMed ID: 30173205
[Abstract] [Full Text] [Related]
10. Bone mineral density and body composition in children with congenital adrenal hyperplasia.
Halper A, Sanchez B, Hodges JS, Kelly AS, Dengel D, Nathan BM, Petryk A, Sarafoglou K.
Clin Endocrinol (Oxf); 2018 Jun 25; 88(6):813-819. PubMed ID: 29460378
[Abstract] [Full Text] [Related]
11. Gender related differences in glucocorticoid therapy and growth outcomes among pubertal children with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH).
Deslauriers JR, Lenz AM, Root AW, Diamond FB, Bercu BB.
J Pediatr Endocrinol Metab; 2012 Jun 25; 25(9-10):977-81. PubMed ID: 23426829
[Abstract] [Full Text] [Related]
12. Effect of long-term glucocorticoid therapy on bone mineral density of the patients with congenital adrenal hyperplasia.
Ünal S, Alikaşifoğlu A, Özön A, Gönç N, Kandemir N.
Turk J Pediatr; 2020 Jun 25; 62(3):359-366. PubMed ID: 32558409
[Abstract] [Full Text] [Related]
13. Long-term follow-up of children with classic congenital adrenal hyperplasia: suggestions for age dependent treatment in childhood and puberty.
Pijnenburg-Kleizen KJ, Thomas CMG, Otten BJ, Roeleveld N, Claahsen-van der Grinten HL.
J Pediatr Endocrinol Metab; 2019 Oct 25; 32(10):1055-1063. PubMed ID: 31573958
[Abstract] [Full Text] [Related]
14. [Comparative study of prednisolone versus hydrocortisone acetate for treatment of patients with the classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency].
Leite FM, Longui CA, Kochi C, Faria CD, Borghi M, Calliari LE, Monte O.
Arq Bras Endocrinol Metabol; 2008 Feb 25; 52(1):101-8. PubMed ID: 18345402
[Abstract] [Full Text] [Related]
15. Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE).
Han TS, Krone N, Willis DS, Conway GS, Hahner S, Rees DA, Stimson RH, Walker BR, Arlt W, Ross RJ, United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE).
Eur J Endocrinol; 2013 Jun 25; 168(6):887-93. PubMed ID: 23520247
[Abstract] [Full Text] [Related]
16. Use of an aromatase inhibitor in children with congenital adrenal hyperplasia: Impact of anastrozole on bone mineral density and visceral adipose tissue.
Halper A, Sanchez B, Hodges JS, Dengel DR, Petryk A, Sarafoglou K.
Clin Endocrinol (Oxf); 2019 Jul 25; 91(1):124-130. PubMed ID: 31070802
[Abstract] [Full Text] [Related]
17. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty.
Bonfig W, Bechtold S, Schmidt H, Knorr D, Schwarz HP.
J Clin Endocrinol Metab; 2007 May 25; 92(5):1635-9. PubMed ID: 17299071
[Abstract] [Full Text] [Related]
18. Growth and development in children with classic congenital adrenal hyperplasia.
Bonfig W.
Curr Opin Endocrinol Diabetes Obes; 2017 Feb 25; 24(1):39-42. PubMed ID: 27898585
[Abstract] [Full Text] [Related]
19. Bone mineral density and body composition in congenital adrenal hyperplasia.
Cameron FJ, Kaymakci B, Byrt EA, Ebeling PR, Warne GL, Wark JD.
J Clin Endocrinol Metab; 1995 Jul 25; 80(7):2238-43. PubMed ID: 7608286
[Abstract] [Full Text] [Related]
20. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.
Verma S, Vanryzin C, Sinaii N, Kim MS, Nieman LK, Ravindran S, Calis KA, Arlt W, Ross RJ, Merke DP.
Clin Endocrinol (Oxf); 2010 Apr 25; 72(4):441-7. PubMed ID: 19486026
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
